So where are we on that coronavirus drug?
Soaring biopharma stocks, breathless press releases, and all-caps presidential tweets all portend a treatment for the novel coronavirus causing a global pandemic. Just when such a thing might come to pass, however, is a complicated matter.
As STAT’s Matthew Herper writes, the world of medicine finds itself between a rock and a hard place when it comes to Covid-19. Readily available treatments, including the President Trump-endorsed hydroxychloroquine and chloroquine, have scant evidence to support them and real side effects to consider. On the other hand, the ideal medicine — a vaccine that would protect people from contracting the virus in the first place — is likely 18 months or more from practical use, if it comes about at all.
In the middle are retrofitted antivirals, repurposed antibodies, and novel applications of proven technologies, each with merits of its own but no guarantee of success.
Read more.
As STAT’s Matthew Herper writes, the world of medicine finds itself between a rock and a hard place when it comes to Covid-19. Readily available treatments, including the President Trump-endorsed hydroxychloroquine and chloroquine, have scant evidence to support them and real side effects to consider. On the other hand, the ideal medicine — a vaccine that would protect people from contracting the virus in the first place — is likely 18 months or more from practical use, if it comes about at all.
In the middle are retrofitted antivirals, repurposed antibodies, and novel applications of proven technologies, each with merits of its own but no guarantee of success.
Read more.
.png)
No hay comentarios:
Publicar un comentario